If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

Share Price is delayed by 15 minutes
Get Live Data
0.40    -0.154 (-27.80%)
Bid:
0.20
Ask:
0.38
Spread: 0.18 (90.00%)
Market Cap: £2.33m
FUM Live PriceLast checked at - London Stock Exchange

Intraday Futura Medical Share Chart

Director's Share Dealing

1 Apr 2011 10:28

RNS Number : 1198E
Futura Medical PLC
01 April 2011
 



For immediate release

1 April 2011

 

 

Futura Medical plc

("Futura" or "the Company")

 

Director's Share Dealing

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, announces that Derek Martin, the Finance Director, has gifted 50,000 ordinary shares to his wife, Julie Martin, at no cost. Separately, each of Mr and Mrs Martin has today sold 50,000 new ordinary shares in the Company at a price of 64p per share.

In a correction to the Company's announcement of 25 March 2011, the exercise price for the options was 41.75p rather than the 43p stated in the release.

Following the transactions, Mr Martin's beneficial and non-beneficial holding in ordinary shares in the Company for the purposes of the AIM Rules for Companies will be 125,000 ordinary shares, representing 0.17% of the Company's share capital.

 

For any further information please contact:

 

Futura Medical plc

 

James Barder, Chief Executive

 

Tel: +44 (0)1483 685 670

mail to: james.barder@futuramedical.com

www.futuramedical.com

 

 

 

Nomura Code Securities Limited

 

Phil Walker / Giles Balleny

Tel:+44 (0)20 7776 1200

 

 

 

For media enquiries please contact:

 

 

 

Buchanan Communications

 

Mark Court / Jessica Fontaine

Tel: +44 (0)20 7466 5000

 

 

Notes to Editors

 

Futura Medical plc

 

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSDKDDBCBKKQQK
Date   Source Headline
22nd Apr 20214:58 pmRNSTR-1: Notification of major holdings
19th Apr 20214:03 pmRNSCorrection – Conversion of Convertible Loan Notes
15th Apr 20212:42 pmRNSConversion of Convertible Loan Notes
14th Apr 20213:40 pmRNSRemuneration of Non-Executive Directors and TVR
14th Apr 20217:00 amRNSFull Year Results for the year ended 31 Dec 2020
1st Apr 20214:20 pmRNSExercise of Warrants, Issue of Equity & TVR
30th Mar 20212:18 pmRNSNotice of Results
25th Mar 20214:41 pmRNSSecond Price Monitoring Extn
25th Mar 20214:36 pmRNSPrice Monitoring Extension
24th Mar 202111:05 amRNSSecond Price Monitoring Extn
24th Mar 202111:00 amRNSPrice Monitoring Extension
24th Mar 20219:05 amRNSSecond Price Monitoring Extn
24th Mar 20219:00 amRNSPrice Monitoring Extension
23rd Mar 20214:41 pmRNSSecond Price Monitoring Extn
23rd Mar 20214:36 pmRNSPrice Monitoring Extension
23rd Mar 20212:05 pmRNSSecond Price Monitoring Extn
23rd Mar 20212:01 pmRNSPrice Monitoring Extension
23rd Mar 20219:05 amRNSSecond Price Monitoring Extn
23rd Mar 20219:00 amRNSPrice Monitoring Extension
22nd Mar 20217:00 amRNSUS FDA Agreement for Confirmatory Clinical study
19th Mar 20214:41 pmRNSSecond Price Monitoring Extn
19th Mar 20214:36 pmRNSPrice Monitoring Extension
19th Mar 202111:06 amRNSSecond Price Monitoring Extn
19th Mar 202111:00 amRNSPrice Monitoring Extension
19th Mar 20217:00 amRNSFutura Receives Recommendation for Approval
4th Mar 20212:05 pmRNSSecond Price Monitoring Extn
4th Mar 20212:00 pmRNSPrice Monitoring Extension
4th Mar 20219:06 amRNSSecond Price Monitoring Extn
4th Mar 20219:00 amRNSPrice Monitoring Extension
4th Mar 20217:00 amRNSFutura Announces Investment & Joint Collaboration
25th Feb 20212:06 pmRNSSecond Price Monitoring Extn
25th Feb 20212:01 pmRNSPrice Monitoring Extension
22nd Feb 20214:41 pmRNSSecond Price Monitoring Extn
22nd Feb 20214:36 pmRNSPrice Monitoring Extension
22nd Feb 20212:05 pmRNSSecond Price Monitoring Extn
22nd Feb 20212:00 pmRNSPrice Monitoring Extension
18th Feb 202111:06 amRNSSecond Price Monitoring Extn
18th Feb 202111:00 amRNSPrice Monitoring Extension
15th Dec 20202:00 pmRNSPrice Monitoring Extension
15th Dec 20209:05 amRNSSecond Price Monitoring Extn
15th Dec 20209:00 amRNSPrice Monitoring Extension
8th Dec 20207:00 amRNSFutura provides US regulatory & commercial update
1st Dec 20207:00 amRNSBlock Listing Six Monthly Return
22nd Oct 20207:00 amRNSFutura provides regulatory and commercial update
21st Sep 20203:12 pmRNSDirector/PDMR Shareholding
16th Sep 20207:00 amRNSInterim Results for Six Months ended 30 June 2020
10th Sep 20204:41 pmRNSSecond Price Monitoring Extn
10th Sep 20204:35 pmRNSPrice Monitoring Extension
17th Aug 20207:00 amRNSNotice of Results
10th Aug 20207:00 amRNSFutura receives positive QMS Audit Opinion

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.